Acrivon 治療公司
US ˙ NasdaqGM ˙ US0048901096

SecurityACRV / Acrivon Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership3,740 shares
Latest Disclosed Value $ 4,450
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 84.60% decrease in ownership of ACRV / Acrivon Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 3,740 shares of Acrivon Therapeutics, Inc. (US:ACRV) valued at $4,451 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 24,281 shares of Acrivon Therapeutics, Inc.. This represents a change in shares of -84.60% during the quarter. The current value of the position is $5,348 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Acrivon Therapeutics EC US0048901096 3,740 -20,541 -84.60 4 -91.84 0.0001
2025-05-28 2025-03-31 NP Acrivon Therapeutics EC US0048901096 24,281 0 0.00 49 -66.44 0.0012
2025-02-25 2024-12-31 NP Acrivon Therapeutics EC US0048901096 24,281 0 0.00 146 -13.61 0.0032
2024-11-26 2024-09-30 NP Acrivon Therapeutics EC US0048901096 24,281 0 0.00 170 20.71 0.0032
2024-08-26 2024-06-30 NP Acrivon Therapeutics EC US0048901096 24,281 7,657 46.06 141 18.64 0.0029
2024-05-28 2024-03-31 NP Acrivon Therapeutics EC US0048901096 16,624 0 0.00 119 45.68 0.0025
2024-02-26 2023-12-31 NP Acrivon Therapeutics EC US0048901096 16,624 0 0.00 82 -48.73 0.0017
2023-11-28 2023-09-30 NP Acrivon Therapeutics EC US0048901096 16,624 3,130 23.20 159 -9.20 0.0041
2023-08-25 2023-06-30 NP Acrivon Therapeutics EC US0048901096 13,494 5,977 79.51 175 83.16 0.0041
2023-05-26 2023-03-31 NP Acrivon Therapeutics EC US0048901096 7,517 7,517 95 0.0025
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.